Epadel OTC Switch Approved With Condition Of Appropriate Use Survey
This article was originally published in PharmAsia News
Japan’s Pharmaceuticals Affairs and Food Sanitation Council’s Committee on Non-prescription Drugs decided that the switch of Mochida Pharmaceuticals hyperlipidemia drug Epadel to an over-the-counter drug will be approved on the condition that a survey on appropriate use is carried out.
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.